Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.08.2010 | Epidemiology

IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls

verfasst von: Li-Xin Qiu, Lei Yao, Hui Yuan, Chen Mao, Bo Chen, Ping Zhan, Kai Xue, Jian Zhang, Xi-Chun Hu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Published data on the association between insulin-like growth factor binding protein 3 (IGFBP3) A-202C polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of 27 studies including 33,557 cases and 45,254 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with IGFBP3 C allele when all studies were pooled into the meta-analysis (CC vs. AA: OR = 1.06, 95% CI = 1.02–1.11; dominant model: OR = 1.04, 95% CI = 1.00–1.07). In the subgroup analysis by ethnicity, significantly increased risk was found for Caucasians (AC vs. AA: OR = 1.04, 95% CI = 1.00–1.08; CC vs. AA: OR = 1.05, 95% CI = 1.01–1.10; dominant model: OR = 1.04, 95% CI = 1.00–1.08) and Asians (CC vs. AA: OR = 1.35, 95% CI = 1.02–1.78; recessive model: OR = 1.38, 95% CI = 1.05–1.82). When stratified by study design, statistically significantly elevated risk was found among population-based studies (CC vs. AA: OR = 1.06, 95% CI = 1.01–1.11; dominant model: OR = 1.03, 95% CI = 1.00–1.07). In the subgroup analysis by menopausal status, no statistically significantly increased risk was found among premenopausal or postmenopausal women. In conclusion, this meta-analysis suggests that the IGFBP3 C allele is a low-penetrant risk factor for developing breast cancer.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMed
2.
Zurück zum Zitat Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMed
3.
Zurück zum Zitat Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMed Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMed
4.
Zurück zum Zitat Schedlich LJ, Graham LD (2002) Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59:12–22CrossRefPubMed Schedlich LJ, Graham LD (2002) Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59:12–22CrossRefPubMed
5.
Zurück zum Zitat Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4:231–239CrossRefPubMed Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4:231–239CrossRefPubMed
6.
Zurück zum Zitat Deal C, Ma J, Wilkin F (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280CrossRefPubMed Deal C, Ma J, Wilkin F (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280CrossRefPubMed
7.
Zurück zum Zitat Jernstrom H, Deal C, Wilkin F (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377–384PubMed Jernstrom H, Deal C, Wilkin F (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377–384PubMed
8.
Zurück zum Zitat The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. doi:10.1007/s10549-009-0489-8 The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. doi:10.​1007/​s10549-009-0489-8
9.
Zurück zum Zitat Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 3:e2578CrossRefPubMed Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 3:e2578CrossRefPubMed
10.
Zurück zum Zitat Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMed Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMed
11.
Zurück zum Zitat Slattery ML, Sweeney C, Wolff R et al (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat 104:197–209CrossRefPubMed Slattery ML, Sweeney C, Wolff R et al (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat 104:197–209CrossRefPubMed
12.
Zurück zum Zitat Al-Zahrani A, Sandhu MS, Luben RN et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10CrossRefPubMed Al-Zahrani A, Sandhu MS, Luben RN et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10CrossRefPubMed
13.
Zurück zum Zitat Canzian F, McKay JD, Cleveland RJ et al (2006) Polymorphisms of genes coding for insulin-like growth factor I and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307CrossRefPubMed Canzian F, McKay JD, Cleveland RJ et al (2006) Polymorphisms of genes coding for insulin-like growth factor I and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307CrossRefPubMed
14.
Zurück zum Zitat Cheng I, Penney KL, Stram DO et al (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:1993–1997CrossRefPubMed Cheng I, Penney KL, Stram DO et al (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:1993–1997CrossRefPubMed
15.
Zurück zum Zitat Rohrbacher M, Risch A, Kropp S et al (2005) The A(-336)C insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 14:289–290PubMed Rohrbacher M, Risch A, Kropp S et al (2005) The A(-336)C insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 14:289–290PubMed
16.
Zurück zum Zitat Wagner K, Hemminki K, Israelsson E et al (2005) Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140CrossRefPubMed Wagner K, Hemminki K, Israelsson E et al (2005) Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140CrossRefPubMed
17.
Zurück zum Zitat Ren ZF, Cai QY, Shu XO et al (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295PubMed Ren ZF, Cai QY, Shu XO et al (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295PubMed
18.
Zurück zum Zitat Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRef
19.
Zurück zum Zitat Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
20.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
21.
Zurück zum Zitat Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17 Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17
22.
Zurück zum Zitat Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed
23.
Zurück zum Zitat Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131(Suppl 11):S3109–S3120 Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131(Suppl 11):S3109–S3120
Metadaten
Titel
IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls
verfasst von
Li-Xin Qiu
Lei Yao
Hui Yuan
Chen Mao
Bo Chen
Ping Zhan
Kai Xue
Jian Zhang
Xi-Chun Hu
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0739-9

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.